Results 31 to 40 of about 6,372 (199)

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treatment of malaria: a randomized trial. [PDF]

, 2007
OBJECTIVES: To compare the efficacy and safety of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) for treating uncomplicated falciparum malaria in Uganda. DESIGN: Randomized single-blinded clinical trial.
Staedke Sarah G, Wabwire-Mangen, F, Yeka Adoke, Rwakimari, JB, Dorsey, Grant, Rwakimari John B, Nosten François, Talisuna, Ambrose O, Dorsey Grant, Kamya, MR, Greenhouse Bryan, Rosenthal, PJ, Greenhouse, B, Rosenthal Philip J, Staedke, SG, Nosten, F, Lugemwa, Myers, Rosenthal, Philip J, Yeka, Adoke, Dorsey, G, Staedke, Sarah G, Greenhouse, Bryan, Rwakimari, John B, Bukirwa, H, Bukirwa, Hasifa, Lugemwa, M, Kamya Moses R, Lugemwa Myers, Kamya, Moses R, Bukirwa Hasifa, Wabwire-Mangen Fred, Talisuna Ambrose O, Wabwire-Mangen, Fred, Talisuna, AO, Nosten, François, Yeka, A   +35 more
core   +1 more source

Reappraising the cardiosafety of dihydroartemisinin-piperaquine [PDF]

The Lancet Infectious Diseases, 2018
The arsenal of efficacious drugs for the treatment of malaria remains small and is clearly insufficient to tackle the global burden of malaria, with more than 216 million clinical episodes and nearly half a million deaths annually.1 Among the new antimalarials that have been developed in the past decade, the artemisinin-based combination ...
Millat Martínez, Pere, Bassat Orellana, Quique   +1 more
openaire   +3 more sources

Piperaquine - Bioanalys, drug metabolism and pharmacokinetics [PDF]

, 2007
Malaria is one of the most abundant parasitic diseases in the world affecting many of the poorest economies. The estimated prevalence is 300 to 700 million clinical episodes each year with up to 3 million deaths.
Tärning, Joel
core   +2 more sources

Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. [PDF]

, 2006
BACKGROUND: Artemisinin-based combinations are judged the best treatments for multidrug-resistant Plasmodium falciparum malaria. Artesunate-mefloquine is widely recommended in southeast Asia, but its high cost and tolerability profile remain obstacles to
Kyaw, M K, Aye, KZ, Phe, O, Smithuis, F, Ashley, E, Kyaw, MK, Htet, L, Lwin, S, Barends, M, Ashley, E A, Stepniewska, K, Singtoroj, T, Lindegardh, N, Aye, K Z, White, NJ, White, Nicholas, White, N J   +16 more
core   +1 more source

Reinfection for dihydroartemisinin-piperaquine.

, 2022
Abbreviations: ALU:artemether-lumefantrine; DHP:dihydroartemisinin-piperaquine; ASAQ:artesunate-amodiaquine; WHO:World Health Organization; PCR:polymerase chain reaction. (DOCX)
Anthony Kapesa (5560253), Jackson Mukonzo (8433558), Gote Swedberg (72692), Vito Baraka (829689), Erasmus Kamugisha (4744887), Karol Marwa (4744893), Evelyne Konje (12225517), Benson Kidenya (3491327)   +7 more
core   +1 more source

Prospective observational study to evaluate the clinical safety of the fixed-dose artemisinin-based combination Eurartesim® (dihydroartemisinin/piperaquine), in public health facilities in Burkina Faso, Mozambique, Ghana, and Tanzania. [PDF]

, 2015
BACKGROUND: The World Health Organization recommends artemisinin-based combination (ACT) for the treatment of uncomplicated malaria. Post-licensure safety data on newly registered ACT is critical for evaluating their risk/benefit profile in malaria ...
Abdulla, Salim, Halidou, Tinto, Ogutu, Bernhards, Mulokozi, Abdunoor, Yawson, Abena, Adjuik, Martin, Baiden, Rita, Owusu-Agyei, Seth, Akparibo, Raymond, Valea, Innocent, Gyapong, Margaret, Macete, Eusebio, Sevene, Esperanca, Smith, Peter, Binka, Fred, Adjei, Alex, Osei, Isaac, Compaoré, Guillaume, Upunda, Gabriel Leonard, Oduro, Abraham, Sie, Ali   +20 more
core   +1 more source

Efficacy and safety of moxidectin, synriam, synriam-praziquantel versus praziquantel against schistosoma haematobium and S. mansoni infections: a randomized, exploratory phase 2 trial [PDF]

, 2016
Schistosomiasis affects millions of people, yet treatment options are limited. The antimalarial Synriam (piperaquine 150 mg/arterolane 750 mg) and the anthelminthic moxidectin revealed promising antischistosomal properties in preclinical or clinical ...
Puchkov, Maxim, Maxim Puchkov, Jennifer Keiser, Jörg Huwyler, Coulibaly, Jean T., Beatrice Barda (717878), Maxim Puchkov (3123930), Jean T Coulibaly, Jan Hattendorf (113923), Jörg Huwyler (166572), Beatrice Barda, Jean T. Coulibaly (108845), Huwyler, Jörg, Hattendorf, Jan, Keiser, Jennifer, Jennifer Keiser (39606), Barda, Beatrice, Jan Hattendorf   +17 more
core   +2 more sources

Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine

International Journal for Parasitology: Drugs and Drug Resistance, 2019
Artemisinin derivatives and their partner drugs in artemisinin combination therapies (ACTs) have played a pivotal role in global malaria mortality reduction during the last two decades.
Duangkamon Loesbanluechai, Namfon Kotanan, Cristina de Cozar, Theerarat Kochakarn, Megan R. Ansbro, Kesinee Chotivanich, Nicholas J. White, Prapon Wilairat, Marcus C.S. Lee, Francisco Javier Gamo, Laura Maria Sanz, Thanat Chookajorn, Krittikorn Kümpornsin   +12 more
doaj   +1 more source

Are k13 and plasmepsin II genes, involved in Plasmodium falciparum resistance to artemisinin derivatives and piperaquine in Southeast Asia, reliable to monitor resistance surveillance in Africa?

Malaria Journal, 2019
Mutations in the propeller domain of Plasmodium falciparum kelch 13 (Pfk13) gene are associated with artemisinin resistance in Southeast Asia. Artemisinin resistance is defined by increased ring survival rate and delayed parasite clearance half-life in ...
Francis Foguim Tsombeng, Mathieu Gendrot, Marie Gladys Robert, Marylin Madamet, Bruno Pradines   +4 more
doaj   +1 more source

A Plasmodium falciparum genetic cross reveals the contributions of pfcrt and plasmepsin II/III to piperaquine drug resistance

mBio
Piperaquine (PPQ) is widely used in combination with dihydroartemisinin as a first-line treatment against malaria. Multiple genetic drivers of PPQ resistance have been reported, including mutations in the Plasmodium falciparum chloroquine resistance ...
John Kane, Xue Li, Sudhir Kumar, Katrina A. Button-Simons, Katelyn M. Vendrely Brenneman, Haley Dahlhoff, Mackenzie A. C. Sievert, Lisa A. Checkley, Douglas A. Shoue, Puspendra P. Singh, Biley A. Abatiyow, Meseret T. Haile, Shalini Nair, Ann Reyes, Rupam Tripura, Thomas J. Peto, Dysoley Lek, Angana Mukherjee, Stefan H. I. Kappe, Mehul Dhorda, Standwell C. Nkhoma, Ian H. Cheeseman, Ashley M. Vaughan, Timothy J. C. Anderson, Michael T. Ferdig   +24 more
doaj   +1 more source